AzTrials
AzTrials

Alzheimer'sREMIND-EUNCT07708675

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - EU

A study testing Symani Surgical System in people with Alzheimer's, run by MMI (Medical Microinstruments, Inc.).

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The objective of this study is to evaluate the safety and feasibility of the Symani System and microsurgical techniques in the deep Cervical Lymph Node (dCLN) region in patients with confirmed Alzheimer's disease. Read more about this study

Who is it for?
Ages 50 to 80 years
Conditions the study is for
Alzheimer's
What is being tested?
Symani Surgical System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
No sites listed yet
Study dates
1 Oct 2026to 1 Mar 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Preoperative Inclusion Criteria:

  1. Patient aged 50 to < 80 years
  2. Patient has confirmed highly probable or probable Alzheimer's disease according to the International Working Group (IWG) Patient and has a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria
  3. Patient has an MMSE score≥ 18
  4. Investigator deems the candidate acceptable for lymphatic surgery with a robotic-assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)
  5. Patients who are of childbearing potential must agree to use a medically acceptable form of contraception.
  6. Patient or their legally authorized representative agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure

Intraoperative Inclusion Criteria:

  1. Intraoperative imaging confirms lymphatic nodes/vessels amenable to reconstruction

Preoperative Exclusion Criteria:

  1. Patient (or their legally authorized representative) is unwilling to provide informed consent
  2. Patient has suspected dementia of other type, e.g., Lewy body, frontotemporal disorder, vascular, etc.
  3. History of head and neck radiation exposure
  4. Patient with severe kidney disease (GFR <30 mL/min/1.73m2)
  5. Patient with acute kidney injury
  6. Active systemic infection under treatment with intravenous antibiotics
  7. Patient has a modified Rankin Score (mRS) of >4
  8. Documented history of clinically significant diagnosis of cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, untreated sleep apnea, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigator's discretion
  9. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease
  10. Patient with an active cancer diagnosis and/or currently receiving treatment for cancer or has received treatment within the past 6 months
  11. Patient is currently receiving treatment or has been treated with anti-amyloid-beta monoclonal antibody therapy within the past 6 months
  12. Patient has contraindication for MRI
  13. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or study outcomes
  14. Patient is ineligible to participate for other reasons in the judgment of the investigator

Intraoperative Exclusion Criteria:

  1. Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - A European, Prospective, Multi-Center, Open Label Study in Alzheimer's Patients

The objective of this study is to evaluate the safety and feasibility of the Symani System and microsurgical techniques in the deep Cervical Lymph Node (dCLN) region in patients with confirmed Alzheimer's disease.

Read the detailed description

A prospective, multicenter open label study, designed to evaluate the Symani System's safety and feasibility for performing microsurgical techniques in the dCLNs to improve clearance of neurotoxins, such as amyloid-beta and phosphorylated tau, in patients with confirmed highly probable or probable Alzheimer's Disease, according to the International Working Group (IWG) and a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria.

Conditions
Alzheimer's
Being tested
Symani Surgical System
Keywords
Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Alzheimer Disease
Medical subject headings
Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Symani Surgical SystemDevice

    Use of Symani Surgical System for performing microsurgical techniques in the deep cervical lymph nodes.

Study groups in NCT07708675
Study groupRoleWhat they receive
Alzheimer's DiseaseExperimentalPatient with confirmed mild to moderate Alzheimer's Disease according to the International Working Group (IWG) and a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria.
Receives: Device: Symani Surgical System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Device-related serious adverse events at 30-days

    All intraoperative and postoperative device-related serious adverse events (SAEs) will be captured from the start of the index procedure through 30 days post-index procedure for each participant. The device-related SAE rate will be reported at 30 days post-index procedure for all evaluable participants.

    Measured: The duration of the participants' index procedure through 30-days post index procedure.

Secondary outcomes (11)
  1. Rate of Serious Adverse Events (SAEs) through 12 months

    All intraoperative and postoperative SAEs, regardless of device relatedness, will be captured from the start of the index procedure through 12 months post-index procedure for each participant. The freedom from SAE rate will be reported through 12 months post-index procedure for all evaluable participants.

    Measured: The duration of the participants' index procedure through 12-months post index procedure.

  2. Rate of Adverse Events (AEs) at 30 days

    All intraoperative and postoperative AEs, regardless of seriousness or device relatedness, will be captured from the start of the index procedure through 30 days post-index procedure for each participant. The freedom from AE rate will be reported at 30 days post-index procedure for all evaluable participants.

    Measured: The duration of the participants' index procedure through 30-days post index procedure.

  3. Incidence of Post Operative Delirium

    Post Operative Delirium occurrence shall be collected from the end of the indexing procedure through discharge, as an AE.

    Measured: From Day 0 visit through 12-24 hours prior to discharge.

  4. Change in Amyloid PET Centiloid Value at 6 and 12- Months

    The centiloid (CL) value of an amyloid positron emission tomography (PET) imaging test will be performed at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit for this comparison.

    Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.

  5. Change in Plasma Biomarkers at 3, 6, and 12 Months: amyloidβ-42 and 40, amyloidβ-42/40 ratio, ptau-217, NfL and GFAP

    Blood panel testing for amyloidβ-42 and 40, amyloidβ-42/40 ratio, ptau-217, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) will be taken at the patient's pre-procedure visit and at the 3, 6, and 12-month follow-up visits.

    Measured: The duration of the participants' pre-procedure visit through 3, 6, and 12-months post index procedure.

  6. Change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score at 6 and 12 Months

    CDR-SB will be evaluated at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit. The CDR-SB scores can take a value between 0 and 18.

    Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.

  7. Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Domains at 6 and 12 Months

    Each of the 6 domains of the CDR-SB -- memory, orientation, judgement, problem solving, community affairs, home and hobbies, and personal care -- will be evaluated at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit.

    Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.

  8. Alzheimer's Disease Assessment Scvale-Cognitive (ADAS-Cog14) at 6 and 12 months

    ADAS-Cog14 will be evaluated at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit. The scores range from 0 to 70.

    Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.

  9. Mini-Mental State Examination (MMSE) at 6 and 12 Months

    MMSE will be evaluated at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit. The scores range from 0 to 30.

    Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.

  10. Activities of Daily Living (ADSC-ADL) at 6 and 12-Months

    ADSC-ADL will be evaluated at the patient's pre-procedure visit and at the 6-month follow-up visit. The scores range from 0 to 78. Questions are asked of the patient's caregiver/family member to best gauge the patient's ability to complete basic and instrumental activities of daily living

    Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.

  11. Change in Zarit Burden Interview (ZBI) at 6 and 12 months

    The ZBI shall be administered at the patient's pre-procedural visit and at the 6 and 12-month visits. This 22-item scale is administered to the patient's caregiver/family member to assess the caregiver's burden.

    Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jul 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completion1 Apr 2028 (estimated)
  4. Study completion1 Mar 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07708675
Sponsor's protocol ID
CDC-00176
Acronym
REMIND-EU
Status last verified
Jul 2026
First submitted
10 Jul 2026
Last updated
16 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Symani Surgical System in people with Alzheimer's, run by MMI (Medical Microinstruments, Inc.).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Clinical Operations (8336646276 ext. 5, clinical.ops@mmimicro.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Device-related serious adverse events at 30-days (time frame: The duration of the participants' index procedure through 30-days post index procedure.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in